Mental and Behavioral Health

Two phase 3 clinical trials form the basis of a supplemental New Drug Application for this indication.

Patrick Alonso, PharmD, CPh, provides some tips for men looking to improve their overall mental health.

The CDC released an alert encouraging pharmacists and providers to counsel patients around the harms of illegal stimulant medications.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, discusses how some of the concern’s raised by the panel can inform future psychedelic research.

Sam Clark, MD, PhD, founder and CEO of Terran Biosciences, talks about some of the problems he saw during the Psychopharmacologic Drugs Advisory Committee meeting.

“The more we share our experiences and stories and work together as a profession, the more we can come together to support each other and form solutions,” said Joanna Lewis, PharmD, MBA, wellness writer and advocate, on overcoming burnout in the pharmacy.

The Psychopharmacologic Drugs Advisory Committee voted 10-1 that the benefits of MDMA do not outweigh its potential risks.

Check out a selection of our coverage from Mental Health Awareness Month.

The drug will be available in pharmacies during the second half of 2024.

Researchers examined the suicide rates of NCAA student-athletes from 2002 to 2022.

Test your pharmacy news knowledge with our weekly quiz.

A single dose of Compass Pathways’ investigational COMP360 was well tolerated and showed durable improvements in CAPS-5 and SDS total scores compared to baseline.

Check out this list of resources to share with patients who are experiencing mental health conditions.

With the mental health crisis worsening in the United States, recent research explores novel treatments and underlying causes.

The drug, TEV-749, demonstrated statistically significant and clinically meaningful efficacy results.

Last August, zuranolone (Zurzuvae) became the first FDA-approved pill to treat postpartum depression in adults.

The Psychopharmacologic Drugs Advisory Committee will meet June 4 to review a new drug application from Lykos Therapeutics.

Two trials studying brexpiprazole in combination with sertraline "constitute one of the largest clinical development programs ever conducted in posttraumatic stress disorder (PTSD)."

A higher patient-rated therapeutic alliance was associated with improvements in depression outcomes up to 1 year after treatment.

Digital therapeutics are positioned as front-runners in the increasingly digital future of health care.

With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?

In the United States, 12 million adults suffer from co-occurring chronic pain and anxiety or depression. Erasing stigmas, educating patients, and tailoring interventions can help to improve outcomes.

After a long hiatus, research in psychedelic medicine is progressing rapidly. With the potential approval of MDMA in the near future, what role will pharmacists play in integrating these new therapies into treatment plans?

See what's trending in pharmacy with a preview the Drug Topics April issue.

Vistagen has enrolled the first participant in the PALISADE-3 phase 3 trial of fasedienol for the treatment of social anxiety disorder.